ArticleJournal of neurology2024
Expanded and independent validation of the NoMoFA scale for Parkinson's disease: the Italian version.
Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs.Movement disorders clinical practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-motor symptoms (NMS) in Parkinson's disease (PD) can fluctuate daily, impacting patient quality of life. The Non-Motor Fluctuation Assessment (NoMoFA) Questionnaire, a recently validated tool, quantifies NMS fluctuations during ON- and OFF-medication states. Our study aimed to validate the Italian version of NoMoFA, comparing its results to the original validation and further exploring its clinimetric properties.
methodsThe scale underwent translation, back-translation, and cognitive pretesting before being administered to a calculated sample of > 200 PD patients. Each patient was assessed using a set of validated measures for assessing PD and cognitive state. We explored NoMoFA's feasibility, acceptability, factorial structure, internal consistency, convergent validity, test-retest reliability (the latter performed on 50 patients after 14 days), and the precision of the scale.
results227 PD patients (mean age 65.34, disease duration 9.31 years) were included, with 100% data computability. The scale was free from floor and ceiling effects, and included 7 factors (59.2% of the variance). Cronbach's alpha coefficient was 0.89, indicating strong internal consistency. The intraclass correlation coefficient (ICC) of 0.90 demonstrated satisfactory reproducibility. The NoMoFA Total score showed the strongest correlations with MDS-UPDRS Parts I (r
conclusionThe Italian version of the NoMoFA scale demonstrated strong reliability, validity and precision, making it a robust tool for assessing non-motor fluctuations in PD.
Indexed as
Identifiers
39733007What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.